The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficasy of Intermittent Oral Administration of High Dose 5'-DFUR After Preoperarive Intratumoral Injection of Krestin (PSK) for Advanced Gastric Cancer.
 
Masato Nakamura
Honoraria - Chugai Pharma; Lilly; Merck; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer; Merck
 
Yoshinori Munemoto
No Relationships to Disclose
 
Masazumi Takahashi
Speakers' Bureau - Chugai Pharma
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Takeshi Kato
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Takeda
Research Funding - Chugai Pharma
Expert Testimony - Lilly
 
Noritaka Minagawa
No Relationships to Disclose
 
Shingo Noura
No Relationships to Disclose
 
Mutsumi Fukunaga
No Relationships to Disclose
 
Hidekazu Kuramochi
No Relationships to Disclose
 
Tetsuo Touyama
No Relationships to Disclose
 
Takao Takahashi
Honoraria - Takeda
 
Yoshito Akagi
No Relationships to Disclose
 
Hironaga Satake
No Relationships to Disclose
 
Shuichi Kurosawa
Employment - Takeda
 
Tomoko Miura
Employment - Takeda
 
Hideyuki Mishima
Honoraria - Takeda
Research Funding - Takeda (Inst)
 
Junichi Sakamoto
Consulting or Advisory Role - Takeda
Travel, Accommodations, Expenses - Takeda
 
Koji Oba
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Ono Pharmaceutical; Takeda
 
Naoki Nagata
No Relationships to Disclose
SAPPHIRE: A randomized phase II study of mFOLFOX6 + panitumumab versus 5-FU/LV + panitumumab after 6 cycles of frontline mFOLFOX6 + panitumumab in patients with colorectal cancer.
 
Hiroaki Kuroda
No Relationships to Disclose